
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Researchers in Austria set out to evaluate the recently proposed and debated characteristic immunohistochemical and ultrastructural features of Kindler's syndrome.